All In Biotech

Drug Trial Radar · NCT07225270

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L Platinum-Based Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 544 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

544

Planned (sponsor's estimate)

Start

Apr 3, 2026

Primary completion

Oct 2028

Study completion May 2030

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Nov 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian cancer. Participants will receive either Rina-S monotherapy (by itself), Rina-S plus bevacizumab, bevacizumab (standard of care) by itself, or no treatment (only monitoring, also standard of care). No participants will be given placebo. Participants will participate in 1 of 2 arms. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 1 to 3 visits at the study clinic for each cycle (duration of cycle is 3 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity and imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) for each participant will be different for every participant.

Conditions

  • Ovarian Cancer
  • Platinum-sensitive Ovarian Cancer
  • PSOC

Interventions

  • Rina-SDrug

    Intravenous (IV) infusion

  • BevacizumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumours (RECIST) 1.1, as Determined by Blinded Independent Central Review (BICR)Time frame: Up to approximately 3 years

Locations

69 sites in 16 countries. Site status is shown where the registry gives one.

  • University Of California Davis Medical Center

    Sacramento, California · Recruiting

  • Hartford Hospital

    Hartford, Connecticut · Recruiting

  • Mt. Sinai Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Florida Cancer Specialists & Research Institute - New Port Richey

    New Port Richey, Florida · Recruiting

  • Sarasota Memorial Health Care System

    Sarasota, Florida · Recruiting

  • Maine Medical Center Cancer Institute Breast Care Center

    Scarborough, Maine · Recruiting

  • Greater Baltimore Medical Center

    Towson, Maryland · Recruiting

  • Missouri Cancer Associates

    Columbia, Missouri · Recruiting

  • Methodist Estabrook Cancer Center

    Omaha, Nebraska · Recruiting

  • Novant Health Presbyterian Medical Center

    Charlotte, North Carolina · Recruiting

  • Miami Valley Hospital South

    Centerville, Ohio · Recruiting

  • Zangmeister Cancer Center

    Columbus, Ohio · Recruiting

  • Penn State Health Milton South Hershey Medical Center

    Hershey, Pennsylvania · Recruiting

  • Alliance Cancer Specialists - Abington Hematology Oncology Associates - Horsham

    Horsham, Pennsylvania · Recruiting

  • Texas Oncology - Northeast Texas

    San Antonio, Texas · Recruiting

  • Virginia Cancer Specialists - Fairfax

    Fairfax, Virginia · Recruiting

  • Prince of Wales Hospital

    Randwick, Australia · Recruiting

  • Medizinische Universitaet Innsbruck

    Innsbruck, Austria · Recruiting

  • Les Cliniques du Sud Luxembourg, Clinique Saint-Joseph

    Arlon, Belgium · Recruiting

  • AZ Maria Middelares

    Ghent, Belgium · Recruiting

  • UZ Leuven - Gasthuisberg Campus

    Leuven, Belgium · Recruiting

  • AZ Delta - Uw Ziekenhuis

    Roeselare, Belgium · Recruiting

  • AZ Nikolaas

    Sint-Niklaas, Belgium · Recruiting

  • Aalborg University Hospital

    Aalborg, Denmark · Recruiting

  • Roskilde Sygehus

    Roskilde, Denmark · Recruiting

  • Kuopion Yliopistollinen Sairaala

    Kuopio, Finland · Recruiting

  • Oulu University Hospital

    Oulu, Finland · Recruiting

  • Tampereen yliopistollinen sairaala - Tampere

    Tampere, Finland · Recruiting

  • Tyks Majakkasairaala

    Turku, Finland · Recruiting

  • Centre Hospitalier de Mont-de-Marsan

    Mont-de-Marsan, France · Recruiting

  • Hôpital Privé du Confluent

    Nantes, France · Recruiting

  • Centre Antoine-Lacassagne - Site Est

    Nice, France · Recruiting

  • Groupe Hospitalier Paris Saint-Joseph

    Paris, France · Recruiting

  • Centre Hospitalier Universitaire de Poitiers

    Poitiers, France · Recruiting

  • Hôpital René Huguenin

    Saint-Cloud, France · Recruiting

  • Klinikum Gütersloh

    Gütersloh, Germany · Recruiting

  • SLK-Kliniken Heilbronn

    Heilbronn, Germany · Recruiting

  • Ospedale Humanitas San Pio X

    Milan, Italy · Recruiting

  • The Jikei University Kashiwa Hospital

    Kashiwa, Japan · Recruiting

  • St Marianna University School of Medicine

    Kawasaki, Japan · Recruiting

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.